Armata submits Phase 3 protocol to FDA for bacteriophage drug AP-SA02

July 20, 2026 7:00 AM

Armata Pharmaceuticals (NYSE American: ARMP) has submitted its complete Phase 3 superiority protocol to the U.S. Food and Drug Administration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found